Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • ROOMS:

Arbitration Awards, Shareholder Meetings, Marketing Agreements, New Appointments and Upcoming Earnings Schedules - Research Report on Valeant, Perrigo, IDEXX, Auxilium, and PerkinElmer

NEW YORK, October 30, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Perrigo Company (NYSE: PRGO), IDEXX Laboratories, Inc. (NASDAQ: IDXX), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and PerkinElmer, Inc. (NYSE: PKI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Valeant Pharmaceuticals International, Inc. Research Report

On October 18, 2013, Valeant Pharmaceuticals International, Inc. (Valeant) announced the interim final award in its formerly disclosed arbitration with Anacor Pharmaceuticals, Inc. (Anacor), with regards to a breach of contract dispute rising out of services provided by Dow Pharmaceutical Sciences, Inc., before its acquisition by Valeant. Valeant informed that it has been ordered to make a one-time payment of $100 million in damages plus costs and fees to Anacor, as a result of the September 2013 hearing. Valeant stated that the arbitrator did not grant an injunction or ongoing royalty, meaning that, while still subject to regulatory approval, the arbitrator's order does not prevent the launch of Jublia® (efinaconazole 10% topical solution). The Company informed that Anacor had sought an award of at least $215 million plus injunctive relief. The Full Research Report on Valeant Pharmaceuticals Intl Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Perrigo Company Research Report

On October 9, 2013, Perrigo Company (Perrigo) announced that its shareholder meeting is scheduled for Monday, November 18, 2013 at 10:00 a.m. at the Company's headquarters at 490 Eastern Avenue in Allegan, Michigan. The Company informed that the meeting is regarding its previously announced acquisition of Elan Corporation, plc to seek shareholder adoption of the transaction agreement and approval of the merger, and related matters. According to Perrigo, holders of its common stock as of 5:00 p.m. ET on October 15, 2013 are entitled to attend and vote at the meeting. The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


IDEXX Laboratories, Inc. Research Report

On October 15, 2013, IDEXX Laboratories, Inc. (IDEXX) announced the appointment of Brian McKeon as its Executive Vice President and CFO, effective January 1, 2014. The Company stated that in his role as CFO, McKeon will be a member of IDEXX's senior executive leadership team and will have oversight of the financial and information technology functions, and report to Jonathan Ayers, IDEXX Chairman, President and CEO. Commenting on the appointment, Ayers stated, "Brian's management experience and demonstrated business acumen, as well as his financial skills and leadership, will be invaluable to IDEXX as we continue to grow and expand our global reach. Due to McKeon's 10 years of experience serving as an IDEXX Board member, he has an in-depth knowledge of the Company, which will be a key advantage as he embarks on this important leadership position within the Company. I am absolutely delighted to have Brian join IDEXX's management in this important role." The Full Research Report on IDEXX Laboratories, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


Auxilium Pharmaceuticals, Inc. Research Report

On October 11, 2013, Auxilium Pharmaceuticals, Inc. (Auxilium) announced that it has signed an agreement with VIVUS, Inc. (VIVUS), under which Auxilium will get exclusive right to market VIVUS' product, STENDRA (avanafil), in the US and Canada. Auxilium informed that both Companies also simultaneously signed a Commercial Supply Agreement pursuant to which VIVUS will be initially responsible for the manufacture and supply of STENDRA to Auxilium. The Company stated that under the license, Auxilium will pay VIVUS a one-time license fee of $30.0 million. Commenting on the agreement, Adrian Adams, President and CEO of Auxilium stated, "We believe STENDRA complements our current portfolio of testosterone replacement therapy and ED products, further broadening our men's health care franchise in a very large market segment consisting of patients that tend to switch among products. We believe the unique features of STENDRA, including its dosing interval (30 minutes prior to sexual activity), ability to take with or without food, modest alcohol consumption requirements and a favorable side effect profile make it an exciting entrant into the category." The Full Research Report on Auxilium Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []


PerkinElmer, Inc. Research Report

On October 4, 2013, PerkinElmer, Inc. (PerkinElmer) announced that it will issue its Q3 2013 earnings results on Wednesday, October 30, 2013, after the market closes. The Company informed that a conference call hosted by Robert F. Friel, Chairman and CEO, and Andy Wilson, Senior Vice President and CFO, will be held on the same day at 5:00 p.m. ET, to discuss the results. PerkinElmer stated that a live audio webcast of the call can be accessed via the Investor section of the Company's website. The Full Research Report on PerkinElmer, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: []



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquiries, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2010-2020 & California Media Partners, LLC. All rights reserved.